December 8, 2025BloodOpen Access

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831

View Full Paper

Ask AI

Bookmark

Authors

RARichard AplencChildren's Hospital of Philadelphia SMSoheil MeshinchiCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa KGKelly GetzUniversity of Pennsylvania

Discussion

Member takes

Implication

Analysis demonstrates reduced relapse rate and equivalent outcomes in low-risk AML patients using fewer chemotherapy cycles, suggesting potential for safer treatment.

Key Points

Comparison revealed a significant decrease in relapse rate for low-risk patients treated with 5 cycles compared to those on 4 cycles.
Two-year relapse rate was lower at 24% for patients receiving 5 cycles on AAML1831 compared to 44% on AAML1031, with p<0.001.
Assessment using multivariable analysis confirmed the importance of a 5th chemotherapy course for certain low-risk patients.
Treatment adjustment may lead to reduced toxicity while maintaining similar survival outcomes, potentially influencing future pediatric AML protocols.

Cite This Study

Aplenc et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e197 https://doi.org/10.1182/blood-2025-878

View Full Paper

Ask AI

Bookmark

Implication

Analysis demonstrates reduced relapse rate and equivalent outcomes in low-risk AML patients using fewer chemotherapy cycles, suggesting potential for safer treatment.

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831

Discussion

Member takes

Implication

Key Points

Cite This Study

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider